Skip to content
Menu

Allarity Therapeutics, Inc. ALLR

Full chart Compare
Set alert

Price alert · ALLR

All alert types
0.88 USD -0.08 (-8.24%)

Regular-session close

0.88 +0.01 +0.82%

After hours · Nov 16, 6:03 PM ET

0.8651 Day range 0.9651
0.769 52-week range 1.84
YTD
-18.96%
1 year
-25.83%
Market cap
13.93M
EPS (ttm)
-0.79
Shares out
4.43M
Forward P/E
-0.02
YTD return
-18.96%
1-year return
-25.83%
50-day average
1.30
Volume
196.91K
Avg volume
120.35K
Open
0.95
Previous close
0.9538
Day's range
0.8651 – 0.9651
52-week range
0.769 – 1.84
Beta
0.29

5D -0.0306 (-3.26%)

0.90000.9500TueWedThuFriMon0.9094

Key statistics

200-day average
28.72
Enterprise value
-15.92M
Free cash flow
-12.94M
Total cash
19.23M
Total debt
1.32M
Return on equity
-121.82%
Short % of float
12.70%

Fundamental scorecard

2 of 25 checks passed on ALLR’s reported financials

ValueGrowthProfitabilityHealthDividend

2of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ALLR Revenue — quarterly 5.00K
ALLR Net income — quarterly -6.20M
ALLR EPS — quarterly -0.39

Earnings

ALLR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-7.71——
Aug 5, 2024Jun 1, 20240.00-3.30——
Aug 5, 2024Jun 1, 20240.00———
May 14, 2024Mar 1, 20240.00———
May 14, 2024Mar 1, 20240.00-664.86——
Mar 8, 2024Dec 1, 20230.00———

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
allarity.com

News

Your note

Sign in to keep a note on ALLR — it syncs with the Stock Master app.

Institution ownership

ALLR institution ownership
Holder% heldSharesValueReported
UBS Group AG0.42%18,45218.73KSep 29, 2024
Tower Research Capital LLC (TRC)0.08%3,4033.45KSep 29, 2024
Bank of America Corporation0.00%1111Sep 29, 2024

Fund ownership

ALLR fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.16%7,1927.30KOct 30, 2024
Fidelity Series Total Market Index Fund0.06%2,6012.64KOct 30, 2024